See What HealthDay Can Do For You
Contact Us

Combo Therapy Helps Black Heart Failure Patients

Reduction in hospitalizations also boosts cost savings

WEDNESDAY, Dec. 14 (HealthDay News) -- In black patients with heart failure, fixed-dose combination therapy using isosorbide dinitrate/hydralazine (ISDN/HYD) not only improves outcomes but also reduces the overall cost of care, according to a study published online Dec. 12 in Circulation: Journal of the American Heart Association.

Derek Angus, M.D., MPH, of the University of Pittsburgh, and colleagues studied data from the African-American Heart Failure Trial (A-HeFT) in which 1,050 subjects from 169 sites were randomly assigned to receive ISDN/HYD or a placebo.

Those in the ISDN/HYD group had a 33% chance of heart failure-related hospitalization versus 47% for the placebo group, which also had a longer mean length of hospital stay (7.9 days versus 6.7 days for the ISDN/HYD group). Excluding the cost of the drugs, the mean per-subject costs related to heart failure were $9,144 for the placebo group and $5,997 for the ISDN/HYD group. Total health care costs were $19,728 and $15,384 for the placebo and ISDN/HYD groups, respectively.

"We found that use of ISDN/HYD therapy in A-HeFT led to fewer hospitalizations, shorter hospitalizations and consequently lower health care costs," the authors conclude. "Even extending to a projected lifetime horizon under the conservative assumption that there would be no benefit beyond the trial, this therapy provided a reference case cost-effectiveness that is still very favorable."

The study was funded by NitroMed, Inc. of Lexington, Mass.

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.